- Predictive Oncology Inc. (POAI) announced **additions to its leadership team and Board of Directors** to support its new digital asset treasury strategy focused on the Aethir (ATH) token.  **[1446159_e85ea4976a044aef844fe8cc7f99c407_0]** 
- **Shawn Matthews**, CEO of DNA Holdings Venture, Inc. and former CEO of Cantor Fitzgerald, was appointed to the **Board of Directors**.  **[1446159_e85ea4976a044aef844fe8cc7f99c407_0]** 
- **Thomas McLaughlin** was named **Chief Investment Officer**, and **Sara Turken, JD**, was appointed **General Counsel**.  **[1446159_e85ea4976a044aef844fe8cc7f99c407_0]** 
- The company's new strategy leverages its AI-driven drug discovery capabilities and a **digital asset treasury focused on the Aethir (ATH) token** to benefit from the growing need for global AI infrastructure.  **[1446159_e85ea4976a044aef844fe8cc7f99c407_0]** **[1446159_e85ea4976a044aef844fe8cc7f99c407_2]**

Predictive Oncology Announces Board and Leadership Appointments for Digital Asset Strategy

- **Predictive Oncology Inc.** announced the **closing of two private investment in public equity transactions (PIPEs)** on **October 7, 2025**, raising approximately **$343.5 million**.  **[1446159_0001171843-25-006348_exh_991.htm:0]** 
- This capital raise supports the Company's new **digital asset treasury strategy**, which will focus on accumulating **ATH**, the native utility token of the Aethir ecosystem.  **[1446159_0001171843-25-006348_exh_991.htm:0]** **[1446159_0001171843-25-006348_exh_991.htm:1]** 
- The **$343.5 million** in proceeds included approximately **$50.8 million in cash** from the Cash PIPE and approximately **$173.3 million in discounted value** (representing a notional value of $292.7 million) from in-kind contributions of locked and unlocked ATH in the Crypto PIPE.  **[1446159_0001171843-25-006348_exh_991.htm:0]** 
- The Company intends to use the in-kind ATH contribution to fund its digital asset treasury strategy and the remaining net proceeds primarily for the **acquisition of ATH in the open market**, as well as for working capital and general corporate purposes.  **[1446159_0001171843-25-006348_exh_991.htm:0]** 
- All share and price per share information in the announcement is presented on a **post-split basis**, following a **one-for-fifteen (1-for-15) reverse stock split** that became effective on **September 30, 2025**.  **[1446159_0001171843-25-006348_exh_991.htm:0]**

Predictive Oncology Announces Closing of Private Placements to Fund Digital Asset Treasury Strategy

- Predictive Oncology Inc. (POAI) is initiating a **digital asset treasury strategy** to acquire and manage digital assets, primarily **ATH**, effective upon the closing of Private Placements.  **[1446159_0001171843-25-006154_f8k_092925.htm:3]** 
- The company has secured a **Private Investment in Public Equity (PIPE) totaling $200 million**, comprising **$100 million in cash and $100 million in-kind**.  **[1446159_0001171843-25-006154_exh_992.htm:8]**  The net cash proceeds from the PIPE will be primarily used to **purchase ATH**.  **[1446159_0001171843-25-006154_f8k_092925.htm:3]** **[1446159_0001171843-25-006154_exh_992.htm:8]** 
- The strategy involves Aethir, described as the **#1 DePIN company by revenue**, generating **over $150 million in Annual Recurring Revenue (ARR)** and demonstrating **96.4% quarter-over-quarter revenue growth in Q1 2025**.  **[1446159_0001171843-25-006154_exh_992.htm:6]**  Aethir operates the **largest GPU network globally** with over **430,000 GPU containers**.  **[1446159_0001171843-25-006154_exh_992.htm:6]** 
- The company acknowledges potential **dilution of outstanding common stock** from the issuance of securities  **[1446159_0001171843-25-006154_exh_101.htm:50]**  and faces regulatory risks, including the possibility of being required to register as a money services business or if digital assets are classified as securities, which could lead to **significant compliance costs or operational shutdowns**.  **[1446159_0001171843-25-006154_exh_993.htm:4]**

Predictive Oncology Inc. Announces Digital Asset Treasury Strategy and $200 Million PIPE

- Predictive Oncology Inc. announced **two private placement transactions** to raise an aggregate of approximately **$344.4 million**.  **[1446159_0001171843-25-006119_exh_991.htm:0]** 
- The funds will be used to initiate a **digital asset treasury strategy** primarily focused on accumulating **Aethir (ATH) tokens**.  **[1446159_0001171843-25-006119_exh_991.htm:0]** 
- The private placements include a **Cash PIPE** of approximately **$51.7 million** and a **Crypto PIPE** involving approximately **$292.7 million** in notional value of Aethir tokens in exchange for pre-funded warrants.  **[1446159_0001171843-25-006119_exh_991.htm:0]** 
- **Shawn Matthews**, CEO of DNA Holdings, is expected to join the Board of Directors upon the closing of the private placements.  **[1446159_0001171843-25-006119_exh_991.htm:0]** 
- A **one-for-fifteen (1-for-15) reverse stock split** of the company's common stock will become effective on **September 30, 2025**.  **[1446159_0001171843-25-006119_exh_991.htm:2]**

Predictive Oncology Inc. Announces $344 Million Private Placements for Digital Asset Treasury Strategy

- Predictive Oncology Inc. (POAI) will effect a **1-for-15 reverse stock split** of its common stock, which was approved by stockholders at a special meeting on **September 19, 2025**.  **[1446159_0001171843-25-006069_exh_31.htm:0]** **[1446159_0001171843-25-006069_exh_991.htm:0]** **[1446159_0001171843-25-006069_f8k_092525.htm:1]** **[1446159_0001171843-25-006069_f8k_092525.htm:2]** 
- The primary purpose of the reverse stock split is to bring the company into compliance with the **Nasdaq minimum bid price requirement** to maintain its listing on the Nasdaq Capital Market.  **[1446159_0001171843-25-006069_exh_991.htm:0]** **[1446159_0001171843-25-006069_exh_991.htm:1]** 
- The reverse stock split will become effective on **September 29, 2025, at 5:00 PM ET**, with the common stock beginning to trade on a split-adjusted basis on **September 30, 2025**.  **[1446159_0001171843-25-006069_exh_31.htm:0]** **[1446159_0001171843-25-006069_exh_991.htm:0]** **[1446159_0001171843-25-006069_f8k_092525.htm:1]** 
- Prior to the split, there were **11,436,201** shares of common stock outstanding; immediately following the split, there will be approximately **762,414** shares outstanding, subject to adjustment for the rounding up of fractional shares.  **[1446159_0001171843-25-006069_exh_991.htm:0]**

Predictive Oncology Announces 1-for-15 Reverse Stock Split

- Predictive Oncology Inc. (POAI) entered into a Securities Purchase Agreement on **August 26, 2025**, for a private placement.  **[1446159_0001171843-25-005680_f8k_082625.htm:1]** 
- The company sold **543,544 shares** of its common stock at a purchase price of **$0.76 per share**.  **[1446159_0001171843-25-005680_f8k_082625.htm:1]** 
- The offering generated approximately **$413,093** in gross proceeds, which will be used for **working capital and general corporate purposes**.  **[1446159_0001171843-25-005680_f8k_082625.htm:1]** 
- As part of the agreement, the company has agreed to certain restrictions on future common stock issuances and granted the investor a 100% participation right in future equity offerings through **October 31, 2025**.  **[1446159_0001171843-25-005680_f8k_082625.htm:1]**

Predictive Oncology (POAI)